» Articles » PMID: 29892158

Modification of α-synuclein by Lipid Peroxidation Products Derived from Polyunsaturated Fatty Acids Promotes Toxic Oligomerization: Its Relevance to Parkinson Disease

Overview
Specialty Biochemistry
Date 2018 Jun 13
PMID 29892158
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Recently, toxic α-synuclein oligomer, which can mediate cell-to-cell propagation is suggested to cause sporadic Parkinson disease. α-Synuclein interacts with membrane lipids especially polyunsaturated fatty acids to stabilize its three-dementional structure. Peroxidation of polyunsaturated fatty acids may reduce their affinity to α-synuclein and peroxidation byproducts might modify α-synuclein. 4-Hydroxy-2-nonenal derived from -6 polyunsaturated fatty acids was reported to modify α-synuclein to produce a toxic oligomer. Moreover, the accumulation of 4-hydroxy-2-nonenal, which could induce oligomeriztion of α-synuclein, was found in parkinsonian brains. Docosahexaenoic acid, an -3 polyunsaturated fatty acids abundant in the neuronal membrane, was also found to enhance α-synuclein oligomerization; however, the precise details of the chemical reaction involved are unclear. Propanoylated lysine, a specific indicator of docosahexaenoic acid oxidation, was increased in neuronal differentiated human neuroblastoma SH-SY5Y cells overexpressing α-synuclein. α-Synuclein might be modified by the peroxidation products and then, is degraded by the autophagy-lysosome system. In addition, in the cells overexpressing α-synuclein, the mitochondrial electrone transfer chain was found to be inhibited. Accumulation of abnormal α-synuclein modified by lipid radicals derived from polyunsaturated fatty acids may be not only an indicator of brain oxidative stress but also causative of neurodegeneration such as Parkinson disease by impairing mitochondrial function.

Citing Articles

Targeting Ferroptosis in Parkinson's Disease: Mechanisms and Emerging Therapeutic Strategies.

Zhou M, Xu K, Ge J, Luo X, Wu M, Wang N Int J Mol Sci. 2024; 25(23).

PMID: 39684753 PMC: 11641825. DOI: 10.3390/ijms252313042.


Targeting ferroptosis with the lipoxygenase inhibitor PTC-041 as a therapeutic strategy for the treatment of Parkinson's disease.

Minnella A, McCusker K, Amagata A, Trias B, Weetall M, Latham J PLoS One. 2024; 19(9):e0309893.

PMID: 39292705 PMC: 11410249. DOI: 10.1371/journal.pone.0309893.


Prosaposin maintains lipid homeostasis in dopamine neurons and counteracts experimental parkinsonism in rodents.

He Y, Kaya I, Shariatgorji R, Lundkvist J, Wahlberg L, Nilsson A Nat Commun. 2023; 14(1):5804.

PMID: 37726325 PMC: 10509278. DOI: 10.1038/s41467-023-41539-5.


What Is the Role of Ferroptosis in Neurodegeneration?.

Benarroch E Neurology. 2023; 101(7):312-319.

PMID: 37580137 PMC: 10437014. DOI: 10.1212/WNL.0000000000207730.


Polymorphic Alpha-Synuclein Oligomers: Characterization and Differential Detection with Novel Corresponding Antibodies.

Moore K, Sengupta U, Puangmalai N, Bhatt N, Kayed R Mol Neurobiol. 2023; 60(5):2691-2705.

PMID: 36707462 PMC: 9883140. DOI: 10.1007/s12035-023-03211-3.


References
1.
Przedborski S, Vila M, Jackson-Lewis V . Neurodegeneration: what is it and where are we?. J Clin Invest. 2003; 111(1):3-10. PMC: 151843. DOI: 10.1172/JCI17522. View

2.
Tarutani A, Suzuki G, Shimozawa A, Nonaka T, Akiyama H, Hisanaga S . The Effect of Fragmented Pathogenic α-Synuclein Seeds on Prion-like Propagation. J Biol Chem. 2016; 291(36):18675-88. PMC: 5009244. DOI: 10.1074/jbc.M116.734707. View

3.
Jucker M, Walker L . Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol. 2011; 70(4):532-40. PMC: 3203752. DOI: 10.1002/ana.22615. View

4.
Winner B, Jappelli R, Maji S, Desplats P, Boyer L, Aigner S . In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A. 2011; 108(10):4194-9. PMC: 3053976. DOI: 10.1073/pnas.1100976108. View

5.
Dexter D, Jenner P . Parkinson disease: from pathology to molecular disease mechanisms. Free Radic Biol Med. 2013; 62:132-144. DOI: 10.1016/j.freeradbiomed.2013.01.018. View